Navigation Links
Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
Date:3/12/2008

MOUNTAIN VIEW, Calif., March 12 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will release results for its fiscal year ended December 31, 2007, on Monday, March 17, 2008, following the close of the U.S. financial markets. The Company will host an investor conference call to discuss the financial results and other clinical development updates at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for two weeks following the event. The conference call, replay and webcast are open to all interested parties.

To access the conference call via the Internet, go to http://www.alexza.com, under the "Investor Relations" link. Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required. Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=P7HYV9G64.

To access the live conference call via phone, dial 1-888-713-4211. International callers may access the live call by dialing 1-617-213-4864. The reference number to enter the call is 10982340.

The replay of the conference call may be accessed via the Internet, at http://www.alexza.com, or via phone at 1-888-286-8010 for domestic callers or 1-617-801-6888 for international callers. The reference number to enter the replay of the call is 76946134.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato(R) system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with Endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

The anticipated conference call will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
2. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
3. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
4. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
5. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
6. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
7. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
8. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
9. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
10. DMetrix and the Armed Forces Radiobiology Research Institute Announce Cooperative Research and Development Agreement
11. Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 18, 2017   Boston Biomedical , an industry ... target cancer stemness pathways, will feature data from two ... the 2017 ASCO Gastrointestinal Cancers Symposium, held from January ... Napabucasin is an orally-administered investigational agent designed ... Cancer stem cells (CSCs) possess the property of ...
(Date:1/18/2017)... ... 2017 , ... Whitehouse Labs has furthered its efforts towards ... (AMRI), the scientific staff dedicated to Extractables / Leachables & Impurities has more ... 2017. Extractable & Leachable evaluations have become increasingly more vital to successful product ...
(Date:1/18/2017)... ... January 18, 2017 , ... BidMed, LLC, ... research and genetic testing lab equipment from two different leading institutes. This highly specialized ... regions of the United States. This 1-day online auction will take place on ...
(Date:1/18/2017)... Jan. 18, 2017  Caris Life Sciences, a ... Foundation, the largest private funder of pancreatic cancer ... evaluating the impact of immunotherapy in the treatment ... enrollment services to identify potential trial candidates based ... treating physicians and study investigators. The Lustgarten Foundation ...
Breaking Biology Technology:
(Date:1/6/2017)... JOLLA, Calif. , Jan. 6, 2017 /PRNewswire/ ... 1 safety studies in healthy volunteers of a ... intended to treat acute pancreatitis. ... is typically a mild disorder, but can be ... organ failure and sepsis, where extended hospital stays, ...
(Date:1/3/2017)... 2017 Onitor, provider of digital health technology ... an innovative biometric data-driven program designed to aid weight ... the 2017 Consumer Electronics Show (CES) in ... U.S., the World Health Organization (WHO), have identified lifestyle ... who are overweight or obese. WHO also states that ...
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL anunció ... acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar a ... con múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el ... de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos ...
Breaking Biology News(10 mins):